Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and apcmin1 mouse intestinal tumorigenesiss

Journal of Pharmacology and Experimental Therapeutics

Volumn 348, Issue 1, 2014, Pages 59-68

  Ravillah, Durgadevi ^a   Mohammed, Altaf ^a   Qian, Li ^a   Brewer, Misty ^a   Zhang, Yuting ^a   Biddick, Laura ^a   Steele, Vernon E ^b   Rao, Chinthalapally V ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AR 42; CELL CYCLE PROTEIN; CELL DIVISION CYCLE HOMOLOG 25C; CYCLIN DEPENDENT KINASE 2; CYCLINE; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CELL CYCLE REGULATION; CELL VIABILITY; CHEMOPROPHYLAXIS; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; INTESTINE CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; CARCINOGENESIS; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HCT116 CELLS; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HUMANS; INTESTINAL NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHENYLBUTYRATES; RATS; RATS, INBRED F344;

EID: 84890541495     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.208645     Document Type: Article

References (49)

1. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, and Kouzarides T (1998) Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391:597-601.
2. Chan HM, Smith L, and La Thangue NB (2001) Role of LXCXE motif-dependent interactions in the activity of the retinoblastoma protein. Oncogene 20:6152-6163.
3. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148-1159.
4. Fodde R, Edelmann W, Yang K, van Leeuwen C, Carlson C, Renault B, Breukel C, Alt E, Lipkin M, and Khan PM, et al. (1994) A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc Natl Acad Sci USA 91:8969-8973.
5. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, and Rosner G, et al. (2005) Final results of a phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxyamic acid, SAHA) in patients with leukemia and myelodysplastic syndrome. Blood 106:785a.
6. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, and Pelicci PG, et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978.
7. Grunstein M (1997) Histone acetylation in chromatin structure and transcription. Nature 389:349-352.
8. Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70.
9. Harms KL and Chen X (2007) Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 67: 3145-3152.
10. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, and Kinzler KW (1998) Identification of c-MYC as a target of the APC pathway. Science 281:1509-1512.
11. He TC, Chan TA, Vogelstein B, and Kinzler KW (1999) PPARdelta is an APCregulated target of nonsteroidal anti-inflammatory drugs. Cell 99:335-345.
12. Hershko T, Chaussepied M, Oren M, and Ginsberg D (2005) Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F. Cell Death Differ 12:377-383.
13. Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, Raju GC, and Hooi SC (2005) Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/ WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 12: 395-404.
14. JiangM and Milner J (2003) Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev 17:832-837.
15. Jin KL, Pak JH, Park JY, Choi WH, Lee JY, Kim JH, and Nam JH (2008) Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissue. J Gynecol Oncol 19:185-190.
16. Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS, and Wu CW (2000) Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 275:20436-20443.
17. Jung KH, Noh JH, Kim JK, Eun JW, Bae HJ, Xie HJ, Chang YG, Kim MG, Park H, and Lee JY, et al. (2012) HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. J Cell Biochem 113:2167-2177.
18. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, and Rosa E, et al. (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9:3578-3588.
19. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore- Cortelli B, Tong W, Secrist JP, and Schwartz L, et al. (2005). Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Clin Oncol 23:3923-3931.
20. Kinzler KW and Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87:159-170.
21. Krämer OH, Göttlicher M, and Heinzel T (2001) Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 12:294-300.
22. Krämer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA, Brill B, Groner B, Bach I, and Heinzel T, et al. (2003) The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 22: 3411-3420.
23. Kouzarides T (2000) Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19:1176-1179.
24. Liu N, He S, Ma L, Ponnusamy M, Tang J, Tolbert E, Bayliss G, Zhao TC, Yan H, and Zhuang S (2013) Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling. PLoS ONE 8:e54001.
25. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, and Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194-202.
26. Markowitz SD and Bertagnolli MM (2009) Molecular basis of colorectal cancer. New Engl J Med 361:2449-2460.
27. Minucci S and Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51.
28. National Cancer Institute (2013) Cancer facts and figures. Available at: http://www.cancer.gov/cancertopics/types/colon-and-rectal. Accessed 12 October 2013.
29. Noh JH, Eun JW, Ryu SY, Jeong KW, Kim JK, Lee SH, Park WS, Yoo NJ, Lee JY, and Nam SW (2006) Increased expression of histone deacetylase 2 is found in human hepatocellular carcinoma. Mol Cell Toxicol 2:166-169.
30. Noh JH, Jung KH, Kim JK, Eun JW, Bae HJ, Xie HJ, Chang YG, Kim MG, Park WS, and Lee JY, et al. (2011) Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS ONE 6:e28103.
31. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, and Horwitz S,, et al. (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24:166-173.
32. Oren M (1999). Regulation of the p53 tumor suppressor protein. J Biol Chem 274: 36031-36034.
33. Pagano M, Pepperkok R, Verde F, Ansorge W, and Draetta G (1992) Cyclin A is required at two points in the human cell cycle. EMBO J 11:961-971.
34. Pagano M, Pepperkok R, Lukas J, Baldin V, Ansorge W, Bartek J, and Draetta G (1993) Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts. J Cell Biol 121:101-111.
35. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, and Esteller M (2003) A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 63: 1114-1121.
36. Reed JC (2002) Apoptosis-based therapies. Nat Rev Drug Discov 1:111-121.
37. Rosenblatt J, Gu Y, and Morgan DO (1992) Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A. Proc Natl Acad Sci USA 89:2824-2828.
38. Roth SY, Denu JM, and Allis CD (2001) Histone acetyltransferases. Annu Rev Biochem 70:81-120.
39. Sharma S, Kelly TK, and Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31:27-36.
40. Shoemaker AR, Gould KA, Luongo C, Moser AR, and Dove WF (1997) Studies of neoplasia in the Min mouse. Biochim Biophys Acta 1332:F25-F48.
41. Shogren-Knaak M, Ishii H, Sun JM, Pazin MJ, Davie JR, and Peterson CL (2006) Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 311:844-847.
42. Sionov RV and Haupt Y (1999) The cellular response to p53: the decision between life and death. Oncogene 18:6145-6157.
43. Strahl BD and Allis CD (2000) The language of covalent histone modifications. Nature 403:41-45.
44. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, and Dove WF (1992) Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256:668-670.
45. Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, and Dietel M, et al. (2008) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98: 604-610.
46. Witt O, Deubzer HE, Milde T, and Oehme I (2009) HDAC family: What are the cancer relevant targets? Cancer Lett 277:8-21.
47. Young J, Jenkins M, Parry S, Young B, Nancarrow D, English D, Giles G, and Jass J (2007) Serrated pathway colorectal cancer in the population: genetic consideration. Gut 56:1453-1459.
48. Zeng Y, Tang CM, Yao YL, Yang WM, and Seto E (1998) Cloning and characterization of the mouse histone deacetylase-2 gene. J Biol Chem 273:28921-28930.
49. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, and Göttlicher M (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5:455-463.